Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy
Stromal reprograming by FAK inhibition overcomes RAS-MAPK inhibition resistance and enhances responses to therapy in pancreas cancer models.